Literature DB >> 10741408

Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis.

Y C Zang1, J Hong, M V Tejada-Simon, S Li, V M Rivera, J M Killian, J Z Zhang.   

Abstract

T cell responses to myelin basic protein (MBP) are potentially involved in the pathogenesis of multiple sclerosis (MS). In this study, we demonstrated that subcutaneous inoculations with irradiated autologous MBP-reactive T cell clones (T cell vaccination) elicited CD8+ anti-idiotypic T cell responses and CD4+ Th2 cell responses in patients with MS. Both regulatory cell types induced by T cell vaccination contributed to the inhibition of MBP-reactive T cells while they differed in the recognition pattern and functional properties. We describe for the first time that the Th2 regulatory cells reacted with activated but not resting T cells in the context of MHC class II molecules and inhibited the proliferation of MBP-reactive T cells through the secretion of IL-4 and IL-10. The T-T cell interaction mediated by Th2 regulatory cells was independent of the antigen specificity of activated T cells. The findings have important implications for our understanding of the regulatory mechanism induced by T cell vaccination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741408     DOI: 10.1002/1521-4141(200003)30:3<908::AID-IMMU908>3.0.CO;2-1

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

1.  Anti-T-cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin-specific T cells.

Authors:  Xiao-Yu Zhang; Xiang-Guo Liu; Wei Wang; Wen-Chao Wang; Xiao-Ming Gao
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

Review 2.  Immunologic therapy for secondary and primary progressive multiple sclerosis.

Authors:  L W Myers
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

3.  Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.

Authors:  Florence Jambou; Wei Zhang; Monique Menestrier; Isabelle Klingel-Schmitt; Olivier Michel; Sophie Caillat-Zucman; Abderrahim Aissaoui; Ludovic Landemarre; Sonia Berrih-Aknin; Sylvia Cohen-Kaminsky
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 4.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis.

Authors:  Jian Hong; Ying C Q Zang; Hong Nie; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

Review 6.  Autologous T-cell vaccination for multiple sclerosis: a perspective on progress.

Authors:  Arthur A Vandenbark; Rivka Abulafia-Lapid
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

7.  DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response.

Authors:  Avishai Mimran; Felix Mor; Pnina Carmi; Francisco J Quintana; Varda Rotter; Irun R Cohen
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 8.  Emerging immunopharmacological targets in multiple sclerosis.

Authors:  Mojtaba Farjam; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2015-09-14       Impact factor: 3.181

9.  T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Authors:  Dimitrios Karussis; Hagai Shor; Julia Yachnin; Naama Lanxner; Merav Amiel; Keren Baruch; Yael Keren-Zur; Ofra Haviv; Massimo Filippi; Panayiota Petrou; Shalom Hajag; Urania Vourka-Karussis; Adi Vaknin-Dembinsky; Salim Khoury; Oded Abramsky; Henri Atlan; Irun R Cohen; Rivka Abulafia-Lapid
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  HSP60 as a target of anti-ergotypic regulatory T cells.

Authors:  Francisco J Quintana; Avishai Mimran; Pnina Carmi; Felix Mor; Irun R Cohen
Journal:  PLoS One       Date:  2008-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.